LETTERS TO
THE EDITOR

Cholecystectomy and bowel function

Editor,—I read with great interest the article by Hearing et al (Gut 1999;45:889–894) on the effect of cholecystectomy on bowel function. In this elegant publication, however, the authors mistakenly assume that published estimates of the effect of cholecystectomy on diarrhoea derive from retrospective or uncontrolled data only. In this context I would like to draw attention to earlier publications derived from the Rotterdam Gallstone Study. 1

In the first paper the results are discussed of a prospective analysis of biliary and gastrointestinal symptoms (including diarrhoea) prior to and up to two years after gall stone therapy. The therapy consisted of either conventional cholecystectomy or extracorporeal shock wave lithotripsy (ESWL), allocated randomly. The second paper focused on surgery and reported on symptoms before and after conventional and laparoscopic cholecystectomy. 2 This study was based on the same concept, and treatment depended on the availability of a laparoscopic set. Generally, we found that the reported incidence of diarrhoea before and after surgery did not change. In fact, there was no difference in the reported incidence of diarrhoea at any time between cholecystectomy and gall bladder preserving therapy (that is, ESWL). We also found that there were no differences in the reported incidence or severity of diarrhoea between laparoscopic and conventional cholecystectomy at any time.

Although the study design of our two studies differed largely from that of Hearing’s, the results and conclusions are in agreement, in that clinical diarrhoea seldom develops after cholecystectomy on bowel function. In this scenario, one would expect eradication of H pylori to lead to regression of the (still antigen and/or T cell dependent) lymphoma. The fact that various (apparently not H pylori related) intestinal as well as extraintestinal lesions regressed with antibiotic treatment is indeed highly suggestive of an underlying infectious process but does not necessarily constitute proof of this assumption, as direct antiproliferative mechanisms of various antibiotics, including clarithromycin, have been reported in different settings. Further investigations are needed before definite recommendations for (as yet empirical) antibiotic therapy in patients with extragastric MALT lymphomas can be given.

M RADERER
Department of Internal Medicine I, Division of Oncology, University of Vienna, Wahringer Guertel 18-20, A-1090 Vienna, Austria

ANDREAS CHOTT
Department of Clinical Pathology, University of Vienna, Wahringer Guertel 18-20, A-1090 Vienna, Austria

Correspondence to: Professor M Raderer.
markus.raderer@akh-wien.ac.at

Guidelines for the management of iron deficiency anaemia

Editor,—It is somewhat self contradictory to suggest that “a transferrin saturation of <30% may help the diagnosis” if there is still doubt about validation of iron deficiency after receipt of the serum ferritin result, the authors having previously acknowledged that the latter is “the most powerful test for iron deficiency” (Gut 2000;46(suppl IV):1–5). Statistical considerations which dictate that serum ferritin will always outrank transferrin in its predictive power have their basis in the comparison between the receiver operating characteristic (ROC) curves for serum ferritin versus transferrin saturation, yielding values of 0.91 versus 0.71 (p<0.001) for the area under the curve. 4 Statistical considerations also dictate acknowledgement of mean corpuscular haemoglobin (MCH) as a predictive entity in its own right following documentation than an alternative to serum ferritin levels only. All low MCV values had low MCH values but never the less transferrin saturation will always outrank transferrin in its predictive power. It is desirable to have a transferrin saturation of >30% to confirm iron deficiency before administering iron therapy.

M S HOPTION CANN
Clinical Biochemistry, Department of Clinical Pathology, Royal Infirmary, Edinburgh, EH3 9YW

Correspondence to: Professor M Hoption Cann.
markus.raderer@akh-wien.ac.at


MALT lymphomas and Helicobacter pylori?

Editor,—Raderer et al (Gut 2000;46:133–5) present an interesting case report of a patient with a mucoassociated lymphoid tissue (MALT) lymphoma of the stomach and descending colon. Their report adds to the growing literature of gastrointestinal MALT lymphomas that respond to antibiotic treatment. In addition to the numerous reports on antibiotic sensitive gastric lymphomas, those of the small intestine, salivary glands, nasal mucosa, and colon 1–7 have recently been reported.

Although Helicobacter pylori is generally implicated as the inducing agent, this does not always appear to be the case. 2 In a recent study, Hiedemann et al 8 has been found in association with gastric MALT lymphomas, including H pylori negative patients whose disease was still responsive to antibiotic treatment. 9 Furthermore, other non-H pylori bacterial and protazooal 10 flora have been observed in gastric lymphomas specific to involved regions. In the report by Raderer et al, and in several of the others previously mentioned, 11 H pylori was not identified in the extragastric lesions, leaving it open to speculation how H pylori may induce antigenic stimulation of these lymphomas. Moreover, in the report by Inoue and Chiba, 12 not only was the rectal lesion H pylori negative but upper gastrointestinal endoscopy was normal. Their patient was seronegative for H pylori and had a negative rapid urease test, culture, and histological examination.

In light of this evidence, it seems that although H pylori may be the most common cause of many gastrointestinal MALT lymphomas, it is not the only causative organism. This is an importante conclusion when compared with patients diagnosed with H pylori negative MALT lymphomas.

S A HOPTION CANN
J P VAN NETTEN
Special Development Laboratory, Royal Jubilee Hospital, Victoria, BC, Canada

C VAN NETTEN
Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC, Canada

Correspondence to: Dr J P van Netten, Special Development Laboratory, Royal Jubilee Hospital, 1900 Fort Street, Victoria, BC, Canada V8R 1J8. hvanetten@caphealth.org

In my own study, comprising 201 subjects with iron deficiency (characterised by serum ferritin <18 µg/l), the MCH conferring optimum trade off between sensitivity (65.2%) and specificity (65.9%) for iron deficiency was <24 pg, and this yielded a positive predictive value of 70%. By contrast, for MCV, optimum trade off between sensitivity (61.7%) and specificity (59.1%) was obtained with a cut off level of <77 fl, giving a positive predictive value of 65%. There were 31 patients with an MCH <26 pg in the presence of an MCV >80 fl compared with only four with a MCV <80 fl in the presence of an MCH >26 pg and, among these, four had an MCH <24 pg in the presence of an MCV >77 fl in contrast with only one with an MCV <77 fl in the presence of an MCH >24 pg. In my study, the most stringent cut off diagnostic level for iron deficiency was a serum ferritin level <10 µg/l found in a subgroup of 145 subjects. At this level, the MCH characterised by optimum trade off between sensitivity (65%) and specificity (66%) was <76 fl (identical with the cut off level in the guidelines), and this yielded a positive predictive value of 55%. Correspondingly, the optimum MCH was either <24 pg, characterised by sensitivities, specificities, and positive predictive values of 74%, 99%, and 80%, respectively, or <23 pg, characterised by sensitivities, specificities, and positive predictive values of 58%, 75%, and 62%, respectively.

Reply

Editor,—Suggesting both that transferrin saturation may help in the diagnosis and that ferritin is the most powerful test for iron deficiency anemia (IDA) is not contradictory. Being the most powerful test does not mean it is always reliable. For example, in inflammatory conditions such as rheumatoid arthritis, ferritin may be normal even if there is iron deficiency.

We find the reference to the greater reliability of mean corpuscular haemoglobin (MCH) compared with mean corpuscular volume (MCV) in diagnosing IDA interesting. We agree that MCH can be useful in the diagnosis of iron deficiency. However, none of the papers quoted takes account of the red cell distribution width (RDW). We wonder if Dr Jolobe would still be able to demonstrate the superiority of MCH compared with MCV if anaemic patients with a normal MCV but raised RDW were excluded. We explain in our guidelines that combined deficiency (that is, iron deficiency together with B12 or folate deficiency) may be associated with a normal MCV and may be recognised by a raised RDW.

O JOLOBE
Department of Medicine for the Elderly, Tameside General Hospital, Ashton under Lyne OL6 9RW, UK.


American College of Gastroenterology 2001 International GI Training Grants Programme

The ACG International GI Training (IGT) Grant Programme provides funding for clinical or clinical research training in gastroenterology and hepatology so that an individual can acquire or develop new cognitive knowledge or a technical skill. This newly acquired knowledge or skill would then be used to improve patient care in the applicant’s geographic area. Physicians outside of the United States and Canada are eligible to apply. At least one fellowship with a maximum of $10,000 per IGT fellowship will be awarded during 2001, for a training period of not less than six months. Awards will be made by a special committee of the ACG and will be based upon the applicant’s credentials, the merit of the proposed training, the training setting, and the potential for enhancing the field of gastroenterology in the applicant’s home country. Application forms can be obtained from the ACG administrative office: 4900B South 31st St, Arlington, Virginia 22206-1656. Tel: +1 703 820 7400; fax: +1 703 931 4520; website: www.acg.gi. Deadline for submission of application is 1 April 2001.

Cleveland Clinic Florida’s Gastroenterology Update 2001

Cleveland Clinic Florida will be sponsoring a postgraduate course entitled “Gastroenterology Update 2001” to be held on 10–11 February 2001 in Fort Lauderdale, Florida, USA. Further information: Sally Jagelman, Manager of Continuing Medical Education, Cleveland Clinic Florida, 3000 West Cypress Creek Road, Fort Lauderdale, FL 33309, USA. Tel: +1 954 978 5539; fax: +1 954 978 5056; email: jagelman@ccf.org

GI malignancies can be prevented and treated: from the bench to the bedside

This international meeting will be held on 14–17 February 2001 in Jerusalem and the Dead Sea, Israel. Further information: Professor Marilyn Katz, Secretariat, GI Malignancies, Target Tours, PO Box 29041, Tel Aviv 61290, Israel. Tel: +972 3 5175150; fax: +972 3 5175151; email: giz@targetconf.com

Redefining Priorities in Gastroenterology

This congress will be held on 11–14 April 2001 in Monte Carlo, Italy. It will be chaired by Professor Massimo Crepaldi (Rome, Italy) and Professor Emamon Quigley (Cork, Ireland). Further information: Maddalena Massaro, Project Leader, AISC-AIM Group, Via A Ristori 38, 00187 Rome, Italy. Tel: +39 06 809686; fax: +39 06 80968829; email: gastro2001@aisc.it.

3rd European Federation of Autonomic Societies (EFAS)

The third European Federation of Autonomic Societies (EFAS) meeting in conjunction with the annual meeting of the sections “Autonomic nervous system” of the German Neurological Society, “Diabetes and Nervous System” of the German Neurological Society, and “Autonomic Nervous System” at the University of Erlangen-Nuremberg, Germany, will be held in Erlangen, Germany on 26–28 April 2001. Further information: Professor Dr M J Hila, Department of Neurology, University or Erlangen-Nuremberg, Schwabachanlage 6, D-91054 Erlangen, Germany. Tel: +49 0131 8534344; fax: +49 9131 8534328; website: www.neurologie.med.uni-erlangen.de/oeffentliche Veranstaltungen.htm

Falk Workshop

The workshop entitled Update in Inflammatory Bowel Diseases will be held in Liubliana, Slovenia, on 5 May 2001. Further information: Prof Dr S Marković, University Medical Center Liubliana, Division of Internal Medicine, Japhjeva 2, 1525 Liubliana, Slovenia. Tel: +386 (1) 231 6925; fax: +386 (1) 433 4190; email: sa.markovic@kclj.si

Gastroenterology and Endotherapy:
XIXth European Workshop

This course, to introduce the experienced gastroenterologist to the growing field of therapeutic endoscopy, will be held on 18–20 June 2001 in Brussels, Belgium. Further information: Mrs Nancy Beauprez, Gastroenterology Department, Erasme Hospital, Route de Lennik 808, B-1070 Brussels. Tel: +32 02 555 49 00; fax: +32 02 555 49 01; email: beauprez@ulb.ac.be

Falk Symposium

The symposium Inflammatory Bowel Disease: A Clinical Case Approach to Pathophysiology, Diagnosis, and Treatment will be held in Bologna, Italy on 22–23 June 2001. Further information: Prof Dr M Campieri, Dr P Gionchetti, Policlinico S. Orsola - Malpighi, Dipartimento di Medicina Interna e Gastroenterologia, Via Massarenti 9, I-40138 Bologna, Italy. Tel: +39 (051) 6364 116 or 6364 122; fax: +39 (051) 392538; email: campieri@med.unibo.it or paolo@med.unibo.it

Summer Abdominal Imaging Conference

A five day course designed for the practising radiologist with a primary interest in abdominal imaging, emphasising the most recent advances in helical CT, MRI, US, and gastrointestinal imaging. It will be held on July 23–27 July 2001 in Banff Springs, Canadian Rockies. Twenty-five category one credit hours. Further information: Janice Ford Benner, University of Pennsylvania Medical Center (Radiology), 3400 Spruce Street, 1 Silverstein Building, Philadelphia, PA 19104, USA. Tel: +1 215 662 6904; fax: +1 215 349 5925.
MALT lymphomas and *Helicobacter pylori*?

S A HOPTION CANN, J P VAN NETTEN and C VAN NETTEN

*Gut* 2001 48: 283
doi: 10.1136/gut.48.2.283a

Updated information and services can be found at:
http://gut.bmj.com/content/48/2/283.2

These include:

**References**

This article cites 10 articles, 0 of which you can access for free at:
http://gut.bmj.com/content/48/2/283.2#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/